Palovarotene

N/A

Report date: 2026/02/24 20:00:16
NME

Base Information

Drug NamePalovarotene
Drug Alias Namepalovaroteno帕罗伐汀palovarotenum帕洛罗汀帕拉罗汀 +[12] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionRetinoic acid receptor gamma agonists
TargetsRetinoic acid receptor gamma
Therapy Area/IndicationsOssification, HeterotopicEmphysemaDry Eye Syndromes +[6] 
Global Approved IndicationsMyositis Ossificans
Approved Indications in ChinaN/A
Original Approved Country/TerritoryCanada
Original Approved Date2022/01/21
Country/TerritoryCzechiaBelgiumBulgaria +[26] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesClementia Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesIpsenIpsen PharmaClementia Pharmaceuticals Inc +[5] 
Inactive CompaniesF. Hoffmann-La Roche Ltd
Active IndicationsOssification, HeterotopicHepatic InsufficiencyMyositis Ossificans
Inactive IndicationsEmphysemaDry Eye SyndromesExostoses, Multiple Hereditary

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG